Chandan Healthcare Ltd
Chandan Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #2 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment. The company targets over 50% year-on-year top-line growth for the next three years, driven by extensive expansion across India.
From Chandan Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment.
- Expansion from 3 to 15 states supports this growth, with several centers and labs under construction, expected to be operational within months.
- Franchise business is a key growth driver, targeting over 1,000 franchises this year and aiming for 3,000 in three years, potentially achieving the target earlier.
2 more points from Chandan Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Chandan Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
- Plans to open eight comprehensive centers and more than five to six labs, along with two PET scans and one genome lab, to be completed before December 2026.
- Total additional capex expected of around INR 10 crores+, to be funded from internal accruals or debt if needed.
- No capital investment required for franchise model; franchisees invest their own capital (~INR 1 lakh) for computer and equipment, paying initial franchise fee (INR 25,000 to 1 lakh) to the company.
2 more points from Chandan Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Chandan Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Chandan Healthcare Ltd said on order book & pipeline — free account, 30 seconds.
Chandan Healthcare Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹65 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Chandan Healthca's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- 2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Chandan Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Chandan Healthcare Ltd Q1 FY27 results?
The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment. The company targets over 50% year-on-year top-line growth for the next three years, driven by extensive expansion across India.
What is Chandan Healthcare Ltd share price analysis?
Chandan Healthcare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 23.1 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.
Is Chandan Healthcare Ltd planning capital expenditure?
Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
Keep Chandan Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.